ArticleNeoplasia (New York, N.Y.)2006
HOXA5 regulates hMLH1 expression in breast cancer cells.
Article in Neoplasia (New York, N.Y.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- HOXA5 inhibits the proliferation of extrahepatic cholangiocarcinoma cells by enhancing MXD1 expression and activating the p53 pathway.Cell death & disease · 2022Article
- New insights in the clinical implication of HOXA5 as prognostic biomarker in patients with colorectal cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- Homeobox Genes in Cancers: From Carcinogenesis to Recent Therapeutic Intervention.Frontiers in oncology · 2021Review
- The relationship of EZH2 and HOXA5 with non-small cell lung carcinoma patient survival rate.Translational cancer research · 2020Article
- HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells.Cancer research · 2016Article
- Hoxa5: A Key Player in Development and Disease.Journal of developmental biology · 2016Review
- HOXA5 indicates poor prognosis and suppresses cell proliferation by regulating p21 expression in non small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2013Article
- The genetic and epigenetic journey of embryonic stem cells into mature neural cells.Frontiers in genetics · 2012Article
- The determination of changes in the expression of genes for selected specific transcriptional factors in in vitro ductal breast cancer cells under the influence of paclitaxel.Cellular & molecular biology letters · 2011Article
- A homeodomain transcription factor regulates the DNA replication checkpoint in yeast.Cell cycle (Georgetown, Tex.) · 2011Article
- Influence of Hoxa5 on p53 tumorigenic outcome in mice.The American journal of pathology · 2010Article
- Neoplasia: the second decade.Neoplasia (New York, N.Y.) · 2008Article
- Frequent alterations of hMLH1 and RBSP3/HYA22 at chromosomal 3p22.3 region in early and late-onset breast carcinoma: clinical and prognostic significance.Cancer science · 2008Article
- Oncogenic role of DDX3 in breast cancer biogenesis.Oncogene · 2008Article
- Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer.Biochemical and biophysical research communications · 2008Article
- Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer.Oncogene · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Homeobox protein HOXA5 functions as a transcriptional factor for genes that are not only involved in segmentation identity but also in cell differentiation. Although HOXA5 has been shown to regulate the expression of the tumor-suppressor protein p53, its role in breast tumorigenesis is not well understood. Using yeast as a model system, we now demonstrate that overexpression of HOXA5 in yeast can be used to identify downstream target genes that are homologous in humans. One such identified gene was that of the mismatch repair pathway component MutL homolog 1. Analysis of the promoter region of the gene for human MutL homolog 1 (hMLH1) displayed several putative HOXA5-binding sites. In transient transfection experiments, the overexpression of HOXA5 transactivated the hMLH1 promoter-reporter construct. In addition, chromatin immunoprecipitation assay using a human breast cancer cell line MCF-7 demonstrated that HOXA5 binds to the hMLH1 promoter in vivo. Furthermore, we demonstrate that, in the presence of HOXA5, there is an increase in in vivo repair activity in MCF-7 cells. Taken together, our results indicate that HOXA5 is a transcriptional regulator of hMLH1 in breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.